Your browser doesn't support javascript.
loading
Efficacy and Safety of Synbiotics in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Randomized, Double-blinded, Placebo-controlled Pilot Study.
Mizutani, Yu; Kawamoto, Shinichiro; Takahashi, Michiko; Doi, Hisayo; Wakida, Kumiko; Tabuchi, Satoko; Tanda, Masaaki; Soga, Akihiro; Chijiki, Ruri; Takakura, Hidetomo; Kawaguchi, Koji; Higashime, Ako; Watanabe, Marika; Ichikawa, Hiroya; Matsumoto, Sakuya; Sakai, Rina; Goto, Hideaki; Kurata, Keiji; Kakiuchi, Seiji; Miyata, Yoshiharu; Uryu, Kiyoaki; Inui, Yumiko; Kitao, Akihito; Yakushijin, Kimikazu; Matsuoka, Hiroshi; Minami, Hironobu.
Affiliation
  • Mizutani Y; Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine and Hospital, Japan.
  • Kawamoto S; Department of Transfusion Medicine and Cell Therapy, Kobe University Hospital, Japan.
  • Takahashi M; Division of Nutrition, Kobe University Hospital, Japan.
  • Doi H; Division of Nursing, Kobe University Hospital, Japan.
  • Wakida K; Division of Nutrition, Kobe University Hospital, Japan.
  • Tabuchi S; Division of Nutrition, Kobe University Hospital, Japan.
  • Tanda M; Department of Pharmacy, Kobe University Hospital, Japan.
  • Soga A; Department of Pharmacy, Kobe University Hospital, Japan.
  • Chijiki R; Department of Medical Oncology/Hematology, Kobe University Hospital, Japan.
  • Takakura H; Department of Medical Oncology/Hematology, Kobe University Hospital, Japan.
  • Kawaguchi K; Department of Medical Oncology/Hematology, Kobe University Hospital, Japan.
  • Higashime A; Department of Medical Oncology/Hematology, Kobe University Hospital, Japan.
  • Watanabe M; Department of Medical Oncology/Hematology, Kobe University Hospital, Japan.
  • Ichikawa H; Department of Medical Oncology/Hematology, Kobe University Hospital, Japan.
  • Matsumoto S; Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine and Hospital, Japan.
  • Sakai R; Department of Medical Oncology/Hematology, Kobe University Hospital, Japan.
  • Goto H; Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine and Hospital, Japan.
  • Kurata K; Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine and Hospital, Japan.
  • Kakiuchi S; Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine and Hospital, Japan.
  • Miyata Y; Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine and Hospital, Japan.
  • Uryu K; Department of Medical Oncology/Hematology, Kobe University Hospital, Japan.
  • Inui Y; Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine and Hospital, Japan.
  • Kitao A; Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine and Hospital, Japan.
  • Yakushijin K; Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine and Hospital, Japan.
  • Matsuoka H; Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine and Hospital, Japan.
  • Minami H; Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine and Hospital, Japan.
Intern Med ; 62(20): 2949-2958, 2023 Oct 15.
Article in En | MEDLINE | ID: mdl-36792187
Objective High-dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT) is an effective treatment option for relapsed and refractory aggressive malignant lymphoma. However, patients frequently experience treatment-induced gastrointestinal symptoms. Synbiotics, including live microorganisms and nondigestible food ingredients, reportedly ameliorate chemotherapy-induced mucosal damage. In this study, we assessed the efficacy and safety of synbiotics in patients undergoing auto-HSCT. Methods This randomized, double-blinded study included patients with malignant lymphoma eligible for auto-HSCT. The patients were randomly assigned to either a synbiotic group receiving Bifidobacterium longum (BB536) and guar gum or a placebo group receiving a placebo containing dextrin. The supplements were administered twice daily from the start of conditioning chemotherapy up to 28 days after auto-HSCT. The primary endpoint was the duration of total parenteral nutrition (TPN). Results In total, 12 patients were included and randomized. The median duration of TPN was 15 (range, 12-33) days in the synbiotic group and 17.5 (range, 0-32) days in the placebo group. The median duration of grade ≥3 diarrhea was shorter in the synbiotic group than in then placebo group (2.5 vs. 6.5 days), as was the duration of hospital stay (31.5 vs. 43 days). The oral intake and quality of life regarding diarrhea and anorexia improved in the synbiotic group after engraftment. Synbiotic infections, including bacteremia, were not observed. Conclusion Synbiotics may reduce gastrointestinal toxicity, thereby reducing nutritional problems and improving the quality of life of patients undergoing auto-HSCT, without severe adverse events.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Synbiotics / Gastrointestinal Diseases / Lymphoma Type of study: Clinical_trials Aspects: Patient_preference Limits: Humans Language: En Journal: Intern Med Journal subject: MEDICINA INTERNA Year: 2023 Document type: Article Affiliation country: Japan Country of publication: Japan

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Synbiotics / Gastrointestinal Diseases / Lymphoma Type of study: Clinical_trials Aspects: Patient_preference Limits: Humans Language: En Journal: Intern Med Journal subject: MEDICINA INTERNA Year: 2023 Document type: Article Affiliation country: Japan Country of publication: Japan